[go: up one dir, main page]

MX2018009247A - Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. - Google Patents

Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.

Info

Publication number
MX2018009247A
MX2018009247A MX2018009247A MX2018009247A MX2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A
Authority
MX
Mexico
Prior art keywords
immunotherapies
histone deacetylase
enhancing
deacetylase inhibitors
inhibitors
Prior art date
Application number
MX2018009247A
Other languages
English (en)
Inventor
Pili Roberto
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2018009247A publication Critical patent/MX2018009247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones que incluyen combinaciones de inhibidores de histona desacetilasa (HDAC) de clase I e inhibidores de proteína de muerte celular programada (PD-1) para mejorar la actividad antiumor. Además se describen métodos para administrar estas composiciones como inmunoterapias para suprimir células T reguladoras en el carcinoma de célula renal.
MX2018009247A 2016-01-28 2017-01-27 Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. MX2018009247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288121P 2016-01-28 2016-01-28
PCT/US2017/015389 WO2017132536A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Publications (1)

Publication Number Publication Date
MX2018009247A true MX2018009247A (es) 2019-03-11

Family

ID=58010402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009247A MX2018009247A (es) 2016-01-28 2017-01-27 Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.

Country Status (13)

Country Link
US (1) US10813919B2 (es)
EP (1) EP3407913A1 (es)
JP (1) JP2019503386A (es)
KR (1) KR20180104122A (es)
CN (1) CN108883179A (es)
AU (1) AU2017211383A1 (es)
BR (1) BR112018015291A2 (es)
CA (1) CA3013047A1 (es)
IL (1) IL260765A (es)
MX (1) MX2018009247A (es)
RU (1) RU2018130831A (es)
WO (1) WO2017132536A1 (es)
ZA (1) ZA201805066B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
EP3635403A4 (en) 2017-06-04 2021-04-21 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER THERAPY AND KIT FOR IT
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
WO2019140296A1 (en) * 2018-01-12 2019-07-18 Viracta Therapeutics, Inc. Epigenetic modifiers for use in cellular immunotherapy
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用
IL310769A (en) 2021-08-11 2024-04-01 Oncohost Ltd Predicting patient response
WO2024231293A1 (en) * 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same
WO2025155922A1 (en) * 2024-01-19 2025-07-24 The Trustees Of Indiana University Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
IL254529B2 (en) * 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
US20180250320A1 (en) * 2015-08-26 2018-09-06 The Johns Hopkins University Compositions and methods for treating solid tumors
CA2994731C (en) * 2015-09-02 2023-09-26 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy

Also Published As

Publication number Publication date
BR112018015291A2 (pt) 2018-12-18
US10813919B2 (en) 2020-10-27
WO2017132536A1 (en) 2017-08-03
AU2017211383A1 (en) 2018-08-16
JP2019503386A (ja) 2019-02-07
EP3407913A1 (en) 2018-12-05
US20190030011A1 (en) 2019-01-31
ZA201805066B (en) 2019-05-29
RU2018130831A3 (es) 2020-04-23
CN108883179A (zh) 2018-11-23
KR20180104122A (ko) 2018-09-19
CA3013047A1 (en) 2017-08-03
RU2018130831A (ru) 2020-03-02
IL260765A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
MX2018009247A (es) Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.
PH12020550622A1 (en) Kras g12c inhibitors
PH12022550469A1 (en) Kras g12d inhibitors
CY1123676T1 (el) Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων
ZA202007007B (en) Mcl-1 inhibitors
WO2019112899A8 (en) IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
CA2971734C (en) Anti-pd-1 antibodies
MX387326B (es) Preparados combinados para el tratamiento contra el cancer o infecciones
MX2018013983A (es) Inhibidores g12c de kras.
MX2021006194A (es) Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
MX395342B (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201992358A1 (ru) Тканеселективная экспрессия трансгена
PH12019550027A1 (en) Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
EA201790968A1 (ru) Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MX394452B (es) Inhibicion de la actividad de olig2.
IN2014MN01944A (es)
MX380835B (es) Terapia de combinación pac-1.
MX2020011470A (es) Metodos de terapia genica.
ZA201901367B (en) Inhibition of olig2 activity
MX2020005251A (es) Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas.